VivoSim Labs (VIVS): Assessing the Road to $1.00 and a Potential +680% Move

Key Takeaways

• VivoSim Labs, Inc. (VIVS) is a San Diego-based biotechnology services company that tests drugs in 3D human liver and intestine tissue models; it is a nano-cap penny stock with effectively no current, credible analyst price targets.
• The $1.00 figure used here is not an analyst consensus. It comes from public discussion of a concrete listing milestone — the Nasdaq minimum bid price threshold — rather than published equity research.
• With the latest verified price near $0.13, a move to $1.00 would require a gain of roughly 680% or more, a very large move for any security.
• The only widely circulated "price target" of $64.80 seen on some aggregator sites is a stale, pre-reverse-split data artifact and is not a usable current target.
• Supportive factors include a $5 million milestone payment from Eli Lilly, first commercial sales in China, and regained Nasdaq listing compliance.
• Principal risks are heavy shareholder dilution, negligible revenue, persistent operating losses, and ongoing sub-$1.00 bid price and delisting pressure.
• Get more context on this ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
• Explore Trending AI Robots to see AI-driven tools traders use to monitor changing market conditions.

Analyst Coverage and the $1.00 Benchmark

VivoSim Labs lacks any meaningful analyst consensus at present. MarketBeat lists no consensus price target (shown as N/A) and carries only a single "Sell" rating from Weiss Ratings, without an accompanying firm target. The $64.80 figure that surfaces on certain aggregator platforms traces back to legacy data from the company's prior identity as Organovo Holdings (ONVO), prior to the 1-for-12 reverse split in March 2025 and the subsequent drop of more than 95%. That figure does not represent any current analyst assessment and should be disregarded.

With insufficient credible targets available, the $1.00 level serves as a practical reference drawn from ongoing public discussion around the Nasdaq minimum bid price rule. This is the listing standard that generally requires a bid price of at least $1.00 to avoid delisting proceedings. It is a technical and compliance milestone rather than a research forecast, yet it remains directly relevant to VIVS given its extended period below that threshold.

Current Valuation and the Scale of the Required Move

At its most recent close near $0.13, VIVS carried a market capitalization of roughly $2.1 million. Reaching $1.00 from that level would imply an appreciation of approximately 680%, a substantial shift by any standard. Trailing twelve-month revenue stood at about $135,000, while the company posted a net loss near $10 million and negative EPS of roughly -$1.53.

Any sustained advance to $1.00 would likely depend on materially higher commercial revenue, additional milestone or partnership income, lower cash burn, and an end to the heavy dilution that has increased the share count by more than 200% over the past year. A further reverse split could lift the price mechanically, but it would not add underlying value for shareholders.

Developments That Could Provide Support

A few concrete developments offer some fundamental footing. The company received a $5 million milestone payment from Eli Lilly linked to a previously divested program, and it recorded its first commercial sales of NAMkind testing services in China. VivoSim's focus on New Approach Methodologies (NAM) using 3D human tissue models aligns with a broader regulatory shift favoring non-animal preclinical testing. The firm has also regained compliance with Nasdaq Listing Rule 5550 on minimum stockholders' equity or market value, easing one near-term delisting worry. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Key Risks That Could Block Progress

The challenges remain considerable. Repeated dilutive financings, including a $4 million public offering and a $4 million private placement with warrants, have expanded the share count and pressured the price. Revenue stays minimal relative to ongoing losses, and the business has yet to show a clear route to profitability. The persistent bid price below $1.00 leaves the company exposed to further Nasdaq scrutiny despite the recent equity compliance achievement. Any shortfall in new financing, slower adoption of its services, or additional dilution would make the path to $1.00 even more difficult.

Technical Picture and Market Structure

The long-term price structure is decidedly negative. The 52-week range runs from roughly $0.12 to a high near $3.40–$5.30, reflecting a decline exceeding 90%. The $1.00 level serves as both a psychological marker and the Nasdaq minimum bid threshold, while the 50-day moving average sits near $0.19, well above the current price. Meaningful support below current levels appears limited beyond the recent lows around $0.12.

Monitoring Points for Investors

Without active analyst coverage, conventional 12-month horizons do not apply. Instead, attention should center on Nasdaq compliance updates, any new financing or reverse-split announcements, quarterly results and cash position, fresh milestone or partnership payments, and commercial progress in China and with existing clients. These factors will shape whether any move toward $1.00 can hold.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI analysis. For a volatile, low-priced name like VIVS, these signals can help identify shifts in momentum more quickly than manual review alone. From what I see, this tool fits naturally into a broader research workflow for monitoring such situations.

Final Assessment

Whether VivoSim Labs can reach $1.00 is ultimately a question of listing compliance and operational survival more than traditional fundamental upside. The $1.00 level reflects a Nasdaq minimum bid benchmark drawn from public discussion rather than analyst estimates, and closing the gap from near $0.13 would require a very large gain of roughly 680%. Support stems from the milestone payment, early China sales, and a favorable regulatory backdrop for non-animal testing, while dilution, minimal revenue, and continued losses represent the primary risks. Investors should focus on financing activity, Nasdaq status, and commercial execution above all else.

Using AI Tools in My Research Process

I find Tickeron's AI Daily Buy/Sell Signals particularly useful when reviewing low-priced, high-volatility names like this one. The platform helps surface momentum changes across a wide universe of securities, which can complement fundamental checks and keep the analysis grounded in real-time market behavior. It has become a regular part of how I evaluate situations where compliance milestones and operational progress intersect.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Allana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume